Dupilumab (DUP) is a monoclonal antibody that inhibits interleukin IL-4 and IL-13 signaling and is approved for type 2 Inflammatory Disease such as asthma, chronic rhinosinusitis with nasal polyposis and atopic dermatitis. Here, IL13 is linked to Nasal polyposis.